Compared to the era of 1 million people with dementia...Roche Korea, Roche Korea, and the Korean Dementia Association signed a business agreement to improve the diagnosis and treatment environment for Alzheimer's disease
Sep 04, 2025
According to the Ministry of Health and Welfare, the number of dementia patients is expected to reach 1 million next year, and the national dementia management cost is close to 0.95% of GDP as of 2023.
As Korea enters a super-aged society, the number of dementia patients is increasing rapidly. Since 2020, it has increased by about 5-7% every year, and in particular, the cost of medical care benefits paid to dementia patients last year was about 2.1793 trillion won, an increase of more than 100 billion won compared to 2023. As such, with aging, the socioeconomic burden caused by dementia is rapidly increasing.
In this regard, Roche Korea, Roche Korea, and the Korean Dementia Association signed a strategic business agreement on the 3rd to improve the diagnosis and treatment environment of Alzheimer's disease, a major cause of dementia.
This agreement is designed to contribute to the creation of an environment for treating and diagnosing Alzheimer's disease at home and abroad based on the expertise and capabilities of each institution amid the increasing burden of disease on Alzheimer's disease patients in Korea due to aging and increasing number of patients.
Through this agreement, the three organizations plan to cooperate ▲ Global clinical R&D cooperation to develop innovative Alzheimer's treatments ▲ Create clinical evidence for early diagnosis and management of Alzheimer's patients ▲ Share expertise and knowledge necessary for the diagnosis and treatment of Alzheimer's disease ▲ Educate and utilize Alzheimer's disease in clinical settings ▲ Create a patient-centered Alzheimer's disease diagnosis policy environment. In addition, based on a broad understanding of Alzheimer's disease biomarkers, the importance of early diagnosis and treatment of diseases will be announced, and awareness and educational activities will be carried out.
Ezat Azem, CEO of Roche Korea, said, `Korea is one of the fastest aging countries in the world, and dementia is becoming a social problem as well as an individual and a family member"Through this agreement, we will take the lead in helping Korean patients maintain their self-interest and making positive changes by promoting the development of new drugs for Alzheimer's disease."
Choi Sung-hye, Chairman of the Korean Dementia Association, said, `With the rapid change in the diagnosis and treatment paradigm of Alzheimer's disease due to the development of medical technology, an integrated approach is needed to raise social awareness and improve the policy environment beyond medical innovation in diagnosis and treatment of Alzheimer's disease"With this business agreement, we will try to lay the foundation for domestic patients to receive the best treatment and management at the best time."
As Korea enters a super-aged society, the number of dementia patients is increasing rapidly. Since 2020, it has increased by about 5-7% every year, and in particular, the cost of medical care benefits paid to dementia patients last year was about 2.1793 trillion won, an increase of more than 100 billion won compared to 2023. As such, with aging, the socioeconomic burden caused by dementia is rapidly increasing.
|
This agreement is designed to contribute to the creation of an environment for treating and diagnosing Alzheimer's disease at home and abroad based on the expertise and capabilities of each institution amid the increasing burden of disease on Alzheimer's disease patients in Korea due to aging and increasing number of patients.
Through this agreement, the three organizations plan to cooperate ▲ Global clinical R&D cooperation to develop innovative Alzheimer's treatments ▲ Create clinical evidence for early diagnosis and management of Alzheimer's patients ▲ Share expertise and knowledge necessary for the diagnosis and treatment of Alzheimer's disease ▲ Educate and utilize Alzheimer's disease in clinical settings ▲ Create a patient-centered Alzheimer's disease diagnosis policy environment. In addition, based on a broad understanding of Alzheimer's disease biomarkers, the importance of early diagnosis and treatment of diseases will be announced, and awareness and educational activities will be carried out.
Ezat Azem, CEO of Roche Korea, said, `Korea is one of the fastest aging countries in the world, and dementia is becoming a social problem as well as an individual and a family member"Through this agreement, we will take the lead in helping Korean patients maintain their self-interest and making positive changes by promoting the development of new drugs for Alzheimer's disease."
Choi Sung-hye, Chairman of the Korean Dementia Association, said, `With the rapid change in the diagnosis and treatment paradigm of Alzheimer's disease due to the development of medical technology, an integrated approach is needed to raise social awareness and improve the policy environment beyond medical innovation in diagnosis and treatment of Alzheimer's disease"With this business agreement, we will try to lay the foundation for domestic patients to receive the best treatment and management at the best time."
This article was translated by Naver AI translator.
